Left ventricular assistant device impella 2.5 usage for patients undergoing high-risk PCI

Catheterization and Cardiovascular Interventions

Volumn 79, Issue 7, 2012, Pages 1135-1137

  Palacios, Igor F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AORTA BALLOON; ARTERIOGRAPHY; CARDIOGENIC SHOCK; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FOLLOW UP; HEART HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MITRAL VALVE REGURGITATION; MORBIDITY; MORTALITY; NOTE; PERCUTANEOUS CORONARY INTERVENTION; QUALITY OF LIFE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

FEMALE; HEART-ASSIST DEVICES; HUMANS; MITRAL VALVE INSUFFICIENCY; MYOCARDIAL INFARCTION; SHOCK, CARDIOGENIC; VENTRICULAR FUNCTION, LEFT;

EID: 84861980907     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24461     Document Type: Note

References (8)

1. Sjaun KD, Engstrom AE, Viss MM, vander Schaaf RJ, Baan J, Koch KT, de Winter RJ, Piek JJ, Tijssen JGP, Heriques JPS. A systematic review and metaanalysis on Intraaortic balloon pump therapy in ST-elevation myocardial infarction: Should we change the guidelines? Eur Heart J 2009;30:459-468.
2. Perera D, Stable R, Thomas M, Booth J, Pitt M, Blackman D, Beder A, Redwood S; the BCIS. Elective intra-aortic balloon counterpulsation during high risk percutaneous coronary intervention. JAMA 2010;304:867-874.
3. Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, Dirschinger J, Kastrati A, Shomimig A. A randomized clinical trial to evalate the safety and efficacy of a percutaneous left ventricular assist devive versus intra-aortic balloon pumping for the treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008;52:1584-1588.
4. Harmon L, Boccalandro F. Cardiogenic Shock secondary to severe acute ischemic mitral regurgitation managed with an Impella 2.5 percutaneous left ventricular assist device. Catheter Cardiovasc Interv 2011 July 29. [Epub ahead of print].
5. Dixon SR, Henriques JPS, Mauri L, Sjauw K, Civitello A, Kar B, Loyalka P, Resnic KS, Teirstein P, Makkar R, Palacios IF, Collins M, Moses J, Benali K, O'Neill WW. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): Initial US experience. J Am Coll Cardiol 2009;2:91-96.
6. Burzotta F, Paloscia L, Trani C, Mascellanti M, Mongiardo R, Materazzo G, Nicoli G, Di Marco M, Leone AM, Porto I, Mazzari MA, Rebuzzi AG, Schiavoni G, Crea F. Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: A pilot two-centre study. J Cardiovasc Med 2008;10:1004-1010.
7. Sjauw KD, Konorza T, Erbel R, Danna PL, Viecca M, Minden HH, Butter C, Hassager C, Machado FP, Pedrazzini G, Wagner DR. Schamberger R, Kerber S, Mathey DG, Schofer J, Engstrom AE, Henriques JPS. Supported high-risk percutaneous coornary intervention with the Impella 2.5 device. The Europella Registry. J Am Coll Cardiol 2009;54:2430-2434.
8. Maini B, Naidu SS, Mulukutla S, Kleiman N, Schreiber T, Wohns D, Dixon S, Rihal C, Dave R, O'Neill W. Real world use of the Impella 2.5 circlatory support system in complex high-risk percutaneous coronary interventions: The Uspella registry. Catheter Cardiovasc Interv 2011;78:8-62.